Jii Bum Lee

18PUBLICATIONS
95CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersHistory of economic thoughtPrecision engineering
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Apr 20, 2026
A Phase II Study of Stereotactic Ablative Radiotherapy plus Atezolizumab plus Tiragolumab in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancer.

|Feb 06, 2026
JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC.

Eun Ji Lee, Ji Ae Ko, Min-Je Kim

|Oct 06, 2025
Mycobacterium tuberculosis-specific T cells restrain anti-cancer drug-induced neutrophilic lung inflammation in tuberculosis.

Kee Woong Kwon, Tae Gun Kang, Jii Bum Lee

|Dec 05, 2024
Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.

Dong Kwon Kim, Chun-Bong Synn, Wongeun Lee

|Nov 04, 2024
Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea.

Joo Sung Shim, Youhyun Kim, Taeho Yuh

|Sep 13, 2024
NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations.

Jessica J Lin, Joshua C Horan, Anupong Tangpeerachaikul

Pageof 3

Frequent Collaborators

8 joint publications

Byoung Chul Cho

6 joint publications

Sun Min Lim

6 joint publications

Min Hee Hong

4 joint publications

Dong Kwon Kim